|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5462990A
(en)
|
1990-10-15 |
1995-10-31 |
Board Of Regents, The University Of Texas System |
Multifunctional organic polymers
|
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
KR100335584B1
(ko)
|
1992-10-28 |
2002-11-29 |
제넨테크, 인코포레이티드 |
혈관내피세포성장인자에대한길항제
|
|
US5830847A
(en)
*
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
|
JPH08504577A
(ja)
|
1992-10-30 |
1996-05-21 |
エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ |
TGF−βの制御活性を改変するための組成物および方法
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
MX9701946A
(es)
|
1997-03-14 |
1998-04-30 |
Arturo Jimenez Bayardo |
Solucion oftalmica transportadora.
|
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
CN104231078A
(zh)
|
1997-04-07 |
2014-12-24 |
基因技术股份有限公司 |
抗-血管内皮生长因子的抗体
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
PT1292335E
(pt)
|
2000-06-23 |
2007-08-13 |
Bayer Schering Pharma Ag |
Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
|
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
KR100976076B1
(ko)
|
2003-05-22 |
2010-08-17 |
아보트 러보러터리즈 |
인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
|
|
RS20150135A1
(sr)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
Tretman sa anti-vegf antitelima
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US20090286271A1
(en)
|
2006-05-31 |
2009-11-19 |
Karumanchi Ananth S |
Methods of Diagnosing and Treating Complications of Pregnancy
|
|
WO2007143023A1
(en)
|
2006-05-31 |
2007-12-13 |
Beth Israel Deaconess Medical Center |
Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
|
|
KR20170012582A
(ko)
|
2006-11-02 |
2017-02-02 |
악셀레론 파마 인코포레이티드 |
Alk1 수용체 및 리간드 길항제 및 그의 용도
|
|
EP2150560A1
(en)
|
2007-06-01 |
2010-02-10 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
|
EP2209003A1
(en)
|
2009-01-16 |
2010-07-21 |
F. Hoffmann-Roche AG |
Means and methods for differentiating between fibrosis and cirrhosis
|
|
US20100210713A1
(en)
*
|
2009-01-16 |
2010-08-19 |
The General Hospital Corporation |
Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
|
|
CN102548617B
(zh)
*
|
2009-03-30 |
2017-11-07 |
阿塞勒隆制药公司 |
Bmp‑alk3拮抗剂和促进骨生长的用途
|
|
WO2010128158A1
(en)
|
2009-05-08 |
2010-11-11 |
Novartis Ag |
Diagnostic biomarkers for fibrotic disorders
|
|
US8795663B2
(en)
|
2010-01-12 |
2014-08-05 |
Beth Israel Deaconess Medical Center, Inc. |
Soluble endoglin and uses thereof
|
|
EP3549952A1
(en)
*
|
2011-04-20 |
2019-10-09 |
Acceleron Pharma Inc. |
Endoglin polypeptides and uses thereof
|
|
WO2013019805A1
(en)
*
|
2011-08-01 |
2013-02-07 |
Tufts Medical Center, Inc. |
Treatment of heart failure and related conditions
|
|
WO2015042269A1
(en)
|
2013-09-20 |
2015-03-26 |
Tufts Medical Center, Inc. |
Methods and compositions for reducing cardiac damage and other conditions
|
|
AU2014339898B2
(en)
|
2013-10-25 |
2020-07-23 |
Acceleron Pharma, Inc. |
Endoglin peptides to treat fibrotic diseases
|
|
AU2015346444A1
(en)
*
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|